PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma-Reference-Cited by-同舟云学术

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma

Published:2015-09-15 Issue:2 Volume:22 Page:470-478
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Sabbatino Francesco,Villani Vincenzo,Yearley Jennifer H.,Deshpande Vikram,Cai Lei,Konstantinidis Ioannis T.,Moon Christina,Nota Sjoerd,Wang Yangyang,Al-Sukaini Ahmad,Zhu Andrew X.,Goyal Lipika,Ting David T.,Bardeesy Nabeel,Hong Theodore S.,Fernandez-del Castillo Carlos,Tanabe Kenneth K.,Lillemoe Keith D.,Ferrone Soldano,Ferrone Cristina R.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models;Journal of Cellular and Molecular Medicine;2024-09

2. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population;European Journal of Cancer;2024-09

3. Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies;Biomarkers in Medicine;2024-08-15

4. The role of immune checkpoint inhibitors in the first-line treatment for patients with advanced biliary tract cancer: a systematic review and meta-analysis of randomized trials;Frontiers in Oncology;2024-07-18

5. DropBlot: single-cell western blotting of chemically fixed cancer cells;Nature Communications;2024-07-13